Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Capital Expenditures: 2009-2025

Historic Capital Expenditures for Lifecore Biomedical (LFCR) over the last 17 years, with May 2025 value amounting to $13.4 million.

  • Lifecore Biomedical's Capital Expenditures fell 22.71% to $2.1 million in Q2 2025 from the same period last year, while for May 2025 it was $13.4 million, marking a year-over-year decrease of 27.07%. This contributed to the annual value of $13.4 million for FY2025, which is 27.07% down from last year.
  • As of FY2025, Lifecore Biomedical's Capital Expenditures stood at $13.4 million, which was down 27.07% from $18.4 million recorded in FY2024.
  • In the past 5 years, Lifecore Biomedical's Capital Expenditures ranged from a high of $29.9 million in FY2022 and a low of $13.4 million during FY2025.
  • In the last 3 years, Lifecore Biomedical's Capital Expenditures had a median value of $18.4 million in 2024 and averaged $17.8 million.
  • Per our database at Business Quant, Lifecore Biomedical's Capital Expenditures rose by 18.70% in 2022 and then declined by 28.25% in 2023.
  • Yearly analysis of 5 years shows Lifecore Biomedical's Capital Expenditures stood at $25.2 million in 2021, then grew by 18.70% to $29.9 million in 2022, then declined by 28.25% to $21.5 million in 2023, then dropped by 14.37% to $18.4 million in 2024, then decreased by 27.07% to $13.4 million in 2025.